When a PE backed group acquires a solo ophthalmology practice, the payout for the selling physician typically falls somewhere between $400,000 and $800,000. The exact number depends on the practice's revenue, payer mix, equipment value, and how much leverage the physician has in the negotiation. For physicians inside a larger group transaction, the leverage is often close to zero because the majority partners control the terms and the smaller practices come along for the ride.
One ophthalmologist received a mid six-figure payout while watching senior partners in the same deal clear several times that amount. His practice was smaller, his patient volume was lower, and he hadn't been part of the group long enough to build equity in shared infrastructure. The number was fair relative to what he had. It just wasn't what he'd imagined when he first heard the word "acquisition."
These payouts often exceed what the practice would fetch on the open market. A solo ophthalmologist generating moderate revenue with a small team isn't the kind of asset that attracts competitive offers through a broker. The PE group pays a premium because it's buying the portfolio, not the individual practice. The physician knows this. They sign because the number beats the alternative, which is usually no offer at all.
The Revenue They Actually Bought
The upfront payment isn't where the real cost lives. The real cost is in the revenue.
When a physician sells their practice to a PE backed group, they don't just sell a patient list, a lease, and some equipment. They sell a percentage of every dollar they'll generate for the duration of their employment with the group. The group's overhead, management fees, corporate allocations, regional infrastructure; all of it gets funded by the revenue that physicians generate in the exam room. Every cataract evaluation, post operative visit, and consultation flows through a corporate structure that takes its cut before the physician sees compensation.
Multiple physicians who've been through this describe the math the same way. They sold a piece of everything they'd bring in for years to come.
Consider the arithmetic over a decade. A full time ophthalmologist inside a PE backed group contributes gross billings that run well above their compensation. The cumulative revenue attributable to one physician's clinical work over that period runs into the millions. A mid 6-figure upfront payment looks very different against that number.
The Weight Just Shifted
Most of these physicians understood the trade at the time. Less administrative burden in exchange for less ownership. The problem is that the administrative burden didn't decrease. The PE group replaced one set of burdens with another. The billing stress was replaced by scheduling mandates and the insurance headaches were replaced by volume targets. The staffing problems they used to handle themselves were replaced by staffing decisions made by people they've never met.
They gave up ownership and a piece of their future revenue stream. In exchange they received a set of constraints that are different from the ones they had before, but no lighter. The weight shifted from self employment stress to institutional stress, so the trap changed shape, but it didn't open.
Run the Second Number
This is the calculation that most physicians don't run before they sign. The upfront payment is easy to evaluate. It's concrete, comparable, and straightforward. The downstream cost of surrendering your revenue stream inside a PE platform is abstract, cumulative, and invisible in the deal documents. It shows up over years, not at closing, and by the time the physician recognizes the full cost, the deal is done and the leverage is gone.
An ophthalmologist considering a practice sale should calculate two numbers before evaluating any offer. The first is the value of the upfront payment relative to the practice's assets and revenue. The second is the total revenue the physician expects to generate over the next 5 to 10 years, and the percentage of that revenue that will be consumed by the acquiring group's overhead, management fees, platform charges, and corporate allocations.
If the second number is larger than the first, and it almost always is, then the buyout wasn't a sale. It was a financing arrangement in which the physician's future production is the collateral, the PE group is the lender, and the upfront payment was an advance against earnings that the physician would've kept in full under independent ownership.
This article is for general educational purposes and is not legal or financial advice.
Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you are evaluating the ophthalmology market and want to understand how different practice models affect transition planning, we are open to thoughtful conversations.
Contact info@verdira.com | 307-381-3734 | verdira.com
